{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T01:28:10Z","timestamp":1793410090438,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T00:00:00Z","timestamp":1727740800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T00:00:00Z","timestamp":1731369600000},"content-version":"vor","delay-in-days":42,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1016\/j.jpba.2024.116381","type":"journal-article","created":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T08:46:58Z","timestamp":1721983618000},"page":"116381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Partial protein binding of uracil and thymine affects accurate dihydropyrimidine dehydrogenase (DPD) phenotyping"],"prefix":"10.1016","volume":"249","author":[{"given":"Sebastian A.H.","family":"van den Wildenberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia A.A.M.","family":"Genet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander S.","family":"Streng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten A.C.","family":"Broeren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten J.","family":"Deenen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost L.J.","family":"van Dongen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Brunsveld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volkher","family":"Scharnhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daan","family":"van de Kerkhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2024.116381_bib1","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1002\/cpt.911","article-title":"Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update","volume":"103","author":"Amstutz","year":"2018","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2024.116381_bib2","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/cpt.1124","article-title":"Therapeutic drug monitoring in oncology: international association of therapeutic drug monitoring and clinical toxicology recommendations for 5-fluorouracil therapy","volume":"105","author":"Beumer","year":"2019","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2024.116381_bib3","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jpba.2024.116381_bib4","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/cpt.2069","article-title":"Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options?","volume":"109","author":"Knikman","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2024.116381_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115027","article-title":"Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions","volume":"221","author":"van den Wildenberg","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116381_bib6","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.2217\/pgs.15.70","article-title":"Translating DPYD genotype into DPD phenotype: Using the DPYD gene activity score","volume":"16","author":"Henricks","year":"2015","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.jpba.2024.116381_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102119","article-title":"Impact of guidelines regarding dihydropyrimidine dehydrogenase (DPD) deficiency screening using uracil-based phenotyping on the reduction of severe side effect of 5-fluorouracil-based chemotherapy: a propension score analysis","volume":"14","author":"Laures","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.jpba.2024.116381_bib8","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/bjc.2017.94","article-title":"Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity","volume":"116","author":"Meulendijks","year":"2017","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.jpba.2024.116381_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpba.2022.115027","article-title":"Quantification of uracil, dihydrouracil, thymine and dihydrothymine for reliable dihydropyrimidine dehydrogenase (DPD) phenotyping critically depend on blood and plasma storage conditions","volume":"221","author":"van den Wildenberg","year":"2022","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116381_bib10","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1111\/cts.12762","article-title":"A simple and rapid UPLC-UV method for detecting DPD deficiency in patients with cancer","volume":"13","author":"Marin","year":"2020","journal-title":"Clin. Transl. Sci."},{"key":"10.1016\/j.jpba.2024.116381_bib11","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.jchromb.2006.02.046","article-title":"High-performance liquid chromatographic assay with UV detection for measurement of dihydrouracil\/uracil ratio in plasma","volume":"834","author":"D\u00e9porte","year":"2006","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116381_bib12","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1177\/147323001003800413","article-title":"The value of dihydrouracil\/uracil plasma ratios in predicting 5-fluorouracilrelated toxicity in colorectal cancer patients","volume":"38","author":"Kristensen","year":"2010","journal-title":"J. Int. Med. Res."},{"key":"10.1016\/j.jpba.2024.116381_bib13","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1373\/clinchem.2007.102251","article-title":"HPLC with UV or mass spectrometric detection for quantifying endogenous uracil and dihydrouracil in human plasma","volume":"54","author":"\u0160vobaite","year":"2008","journal-title":"Clin. Chem."},{"key":"10.1016\/j.jpba.2024.116381_bib14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/bmc.2741","article-title":"LC-MS\/MS method for simultaneous analysis of uracil, 5,6-dihydrouracil, 5-fluorouracil and 5-fluoro-5,6-dihydrouracil in human plasma for therapeutic drug monitoring and toxicity prediction in cancer patients","volume":"27","author":"B\u00fcchel","year":"2013","journal-title":"Biomed. Chromatogr."},{"key":"10.1016\/j.jpba.2024.116381_bib15","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/FTD.0b013e318240405f","article-title":"A rapid HPLC-ESI-MS\/MS method for determination of dihydrouracil\/uracil ratio in plasma: Evaluation of toxicity to 5-flurouracil in patients with gastrointestinal cancer","volume":"34","author":"C\u00e9sar","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2024.116381_bib16","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.jpba.2017.04.055","article-title":"Development, validation and application of a novel liquid chromatography tandem mass spectrometry assay measuring uracil, 5,6-dihydrouracil, 5-fluorouracil, 5,6-dihydro-5-fluorouracil, \u03b1-fluoro-\u03b2-ureidopropionic acid and \u03b1-fluoro-\u03b2-alanine in human plasma","volume":"142","author":"Chavani","year":"2017","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116381_bib17","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/chromsci\/bms085","article-title":"Validation of an ultra-high performance liquid chromatography tandem mass spectrometric method for quantifying uracil and 5,6-Dihydrouracil in human plasma","volume":"50","author":"Coudor\u00e9","year":"2012","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2024.116381_bib18","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jpba.2016.04.039","article-title":"Development and validation of a rapid and sensitive UPLC-MS\/MS method for determination of uracil and dihydrouracil in human plasma","volume":"126","author":"Jacobs","year":"2016","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116381_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.jchromb.2020.122038","article-title":"Automatic quantification of uracil and dihydrouracil in plasma","volume":"1142","author":"Robin","year":"2020","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116381_bib20","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1097\/FTD.0000000000000768","article-title":"Phenotyping of uracil and 5-fluorouracil metabolism using LC-MS\/MS for prevention of toxicity and dose adjustment of fluoropyrimidines","volume":"42","author":"Tafzi","year":"2020","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.jpba.2024.116381_bib21","article-title":"Pre-analytical considerations for the analysis of uracil and 5,6-dihydrouracil in heparin plasma","volume":"0","author":"Capiau","year":"2022","journal-title":"Clin. Chem. Lab. Med."},{"key":"10.1016\/j.jpba.2024.116381_bib22","article-title":"Quantitative impact of pre-analytical process on plasma uracil when testing for dihydropyrimidine dehydrogenase deficiency","author":"Maillard","year":"2022","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116381_bib23","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cca.2022.10.017","article-title":"Instability of uracil in whole blood might affect cancer treatment with fluoropyrimidines","volume":"538","author":"Tybirk","year":"2023","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.jpba.2024.116381_bib24","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S1570-0232(02)00009-0","article-title":"Measurement of endogenous uracil and dihydrouracil in plasma and urine of normal subjects by liquid chromatography\u2013tandem mass spectrometry","volume":"769","author":"Jiang","year":"2002","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2024.116381_bib25","doi-asserted-by":"crossref","DOI":"10.1002\/cpt.2608","article-title":"Dihydropyrimidine dehydrogenase phenotyping using pretreatment uracil: a note of caution based on a large prospective clinical study","author":"de With","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jpba.2024.116381_bib26","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2710.2004.00569.x","article-title":"A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity","volume":"29","author":"Ciccolini","year":"2004","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.jpba.2024.116381_bib27","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1111\/bcp.13719","article-title":"Food-effect study on uracil and dihydrouracil plasma levels as marker for dihydropyrimidine dehydrogenase activity in human volunteers","volume":"84","author":"Henricks","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.jpba.2024.116381_bib28","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/j.clinbiochem.2015.04.019","article-title":"Improved determination of uracil and dihydrouracil in plasma after a loading oral dose of uracil using high-performance liquid chromatography with photodiode array detection and porous graphitic carbon stationary phase","volume":"48","author":"Hahn","year":"2015","journal-title":"Clin. Biochem."},{"key":"10.1016\/j.jpba.2024.116381_bib29","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1570-0232(02)00914-5","article-title":"Optimization of protein precipitation based upon effectiveness of protein removal and ionization effect in liquid chromatography-tandem mass spectrometry","volume":"785","author":"Polson","year":"2003","journal-title":"J. Chromatogr. B Anal. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.jpba.2024.116381_bib30","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1016\/j.jpba.2004.03.005","article-title":"Protein precipitation for the analysis of a drug cocktail in plasma by LC-ESI-MS","volume":"35","author":"Souverain","year":"2004","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.jpba.2024.116381_bib31","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/bja\/aei293","article-title":"Changes in the effect of propofol in response to altered plasma protein binding during normothermic cardiopulmonary bypass","volume":"96","author":"Takizawa","year":"2006","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.jpba.2024.116381_bib32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1093\/chromsci\/33.7.377","article-title":"Determination of propofol in blood by hplc. comparison of the extraction and precipitation methods","volume":"33","author":"Dawidowicz","year":"1995","journal-title":"J. Chromatogr. Sci."},{"key":"10.1016\/j.jpba.2024.116381_bib33","series-title":"Tietz Fundamentals of Clinical Chemistry & Molecular Biology","author":"Burtis","year":"2008"},{"key":"10.1016\/j.jpba.2024.116381_bib34","doi-asserted-by":"crossref","first-page":"947","DOI":"10.5858\/2002-126-0947-PEOMOI","article-title":"pH effects on measurements of ionized calcium and ionized magnesium in blood","volume":"126","author":"Wang","year":"2002","journal-title":"Arch. Pathol. Lab. Med."},{"key":"10.1016\/j.jpba.2024.116381_bib35","doi-asserted-by":"crossref","DOI":"10.1007\/s00280-023-04518-7","article-title":"Assay performance and stability of uracil and dihydrouracil in clinical practice","author":"Knikman","year":"2023","journal-title":"Cancer Chemother. Pharmacol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524004217?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708524004217?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,12]],"date-time":"2024-11-12T10:54:11Z","timestamp":1731408851000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708524004217"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10]]},"references-count":35,"alternative-id":["S0731708524004217"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116381","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2024,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Partial protein binding of uracil and thymine affects accurate dihydropyrimidine dehydrogenase (DPD) phenotyping","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical and Biomedical Analysis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpba.2024.116381","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"116381"}}